Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARG | Q86W56 | 1/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.55 |
| ▸ | PKM | P14618 | 2/20 | 0.54 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.54 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.53 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.53 |
| ▸ | GRIN1 | Q05586 | 8/20 | 0.53 |
| ▸ | GRIN2B | Q13224 | 8/20 | 0.53 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11223477 | 0.86 | GABRA1 (0.58) | PARGGABRA5GABRA1GRIN1GRIN2B | |
| SCHEMBL19555085 | 0.84 | MAPK8 (0.66) | PARGSLC9A1 | |
| SCHEMBL7653703 | 0.81 | PKM (0.48) | PKMMAPK10GABRA5GABRA1 | |
| SCHEMBL17825280 | 0.79 | PARG (0.57) | PARGGABRA5GABRA1GRIN1GRIN2B | |
| SCHEMBL27605941 | 0.79 | PARG (0.60) | PARGHIF1AGRIN1GRIN2BALDH1A1 | |
| SCHEMBL17241596 | 0.78 | TSHR (0.62) | SLC9A1ALDH1A1 | |
| SCHEMBL6509732 | 0.78 | MEN1 (0.60) | SLC9A1 | |
| SCHEMBL6978785 | 0.77 | TSHR (0.51) | PKMMAPK10GABRA5GABRA1 | |
| SCHEMBL19785223 | 0.76 | PARG (0.58) | PARGSLC9A1 | |
| SCHEMBL3419641 | 0.75 | PKM (0.58) | PKMMAPK10GABRA5GABRA1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050004126-A1 | Method of determining potential allosterically-binding matrix metalloproteinase inhibitors | ANDRIANJARA CHARLES (FR) | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004126-A1 | Method of determining potential allosterically-binding matrix metalloproteinase inhibitors | MMP13, MMP12, MMP25 | PARG 4866/4885HIF1A 2128/4885PKM 2902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.